Skip to main content
Caplight Logo









Hemo China

Hemo China

Private
BeijingHealthcare & Life Scienceshttps://www.hemocorp.com/

Last Round

Series C

Jan 5, 2021

Est. Valuation

$456.4M

Total Funding Raised

$138.5M

Company Overview

Hemo China is a medical device company that develops and manufactures innovative interventional solutions for cerebrovascular and peripheral vascular diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

neuro-interventional devicesstroke treatmentaspiration catheterstent retrieverneurovascular devicesmedical device manufacturingOEMcerebrovascular diseaseballoon cathetermedtechregulatory consultingmarket access servicesinterventional radiologyminimally invasive surgery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hemo China Comparables

Compare Hemo China with similar companies based on industry and business-model similarity.

Hemo China comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeuroSafe Medical Co., Ltd.
88%
Wallaby Medical
84%
MicroPort Scientific Corporation
83%

Hemo China Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 5, 2021
Series BOct 10, 2020
Series A ExtensionApr 25, 2020
Series ASep 22, 2017

Hemo China Investors

Notable investors and investment history

Hemo China investors
InvestorRounds
3H Health InvestmentSeries C, Series B
OrbiMedSeries C
Legend CapitalSeries B
Trustbridge PartnersSeries C
Hudson Bay Capital ManagementSeries C
Lilly Asia VenturesSeries C
Octagon CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 25, 2020

    $12M round raised at $98M post-money valuation.

  • Sep 22, 2017

    Raised $27M in Series A funding.

Hemo China Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hemo China Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hemo China's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range12
Year Founded2017
Last FundingJan 5, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?